Should adjuvant chemotherapy be used to treat breast cancer in elderly patients (&gt; or = 70 years of age)? (Q74202003)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Should adjuvant chemotherapy be used to treat breast cancer in elderly patients (> or = 70 years of age)? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

L Balducci

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M Extermann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

I Fentiman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

S Monfardini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

F Perrone

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 October 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

1720-1724

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

The effect of comorbidity on 3-year survival of women with primary breast cancer

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Adjuvant therapy of breast cancer: a Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900297-9

7 January 2021

10.1016/S0959-8049(97)00297-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9470824%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference